The U.S. Food and Drug Administration (FDA) has approved Jascayd (Nerandomilast), a novel phosphodiesterase 4 (PDE4) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. IPF is a chronic, progressive lung disease characterized by scarring of lung tissue, which leads to declining lung function and ultimately, respiratory failure.
Jascayd works by selectively inhibiting the PDE4B isoenzyme, helping to increase intracellular cyclic adenosine monophosphate (cAMP) levels. This action reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, key contributors to fibrosis in IPF. The drug’s dual anti-fibrotic and immunomodulatory properties make it a promising new therapeutic option for patients with this difficult-to-treat condition.
Jascayd’s approval was supported by two major randomized, double-blind, placebo-controlled trials—FIBRONEER-IPF and Trial 2, in patients with idiopathic pulmonary fibrosis (IPF), with or without background antifibrotic therapy such as Nintedanib or Pirfenidone. Across these studies, Jascayd 18 mg twice daily demonstrated a significant reduction in lung function decline, as measured by forced vital capacity (FVC) and showed a favorable safety profile, confirming its efficacy as a novel PDE4B-selective treatment for slowing disease progression in IPF.
The recommended dosage is 18 mg twice daily, taken approximately 12 hours apart, with or without food. For patients who experience intolerance, the dose may be reduced to 9 mg twice daily, except when used alongside Pirfenidone. Jascayd tablets can be swallowed whole or dispersed in water.
The FDA’s approval introduces a new class of therapy for IPF, providing hope for improved management and potentially better outcomes for patients living with this progressive disease.
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis or endorsement of any specific treatment. Patients should consult a qualified healthcare professional before starting or changing any medication. All treatments should be used according to medical guidance and local regulatory approvals.
